View sample - Report Buyer

1 Table of contents
1 Table of contents................................................................................................................................... 3
1.1 List of Tables .................................................................................................................................. 5
1.2 List of Figures ................................................................................................................................. 5
2 Type 1 Diabetes Therapeutics Market: Market Characterization........................................................... 6
2.1 Overview......................................................................................................................................... 6
2.2 Type 1 Diabetes Market Size.......................................................................................................... 6
2.3 Type 1 Diabetes Therapeutics Market Forecast and CAGR........................................................... 7
2.4 Drivers and Barriers for the Type 1 Diabetes Therapeutics Market ................................................ 8
2.4.1 Drivers for the Type 1 Diabetes Therapeutics Market ........................................................... 8
2.4.2 Restraints for the Type 1 Diabetes Therapeutics Market....................................................... 9
2.5 Opportunity and Unmet Need ........................................................................................................10
2.6 Key Takeaway ...............................................................................................................................11
3 Type 1 Diabetes Therapeutics Market: Competitive Assessment ........................................................12
3.1 Overview........................................................................................................................................12
3.2 Strategic Competitor Assessment..................................................................................................12
3.3 Product Profile for the Major Marketed Products in the Type 1 Diabetes Disease Market.............13
3.3.1 Lantus (Insulin Glargine) ......................................................................................................13
3.3.2 Humulin (Human Insulin) ......................................................................................................16
3.3.3 Humalog (Insulin Lispro).......................................................................................................17
3.3.4 Novolog (Insulin Aspart) .......................................................................................................19
3.3.5 Novolin (Human Insulin) .......................................................................................................20
3.3.6 Apidra (Insulin Glulisine).......................................................................................................21
3.3.7 Levemir (Insulin Detemir)......................................................................................................23
3.4 Key Takeaway ...............................................................................................................................25
4 Type 1 Diabetes Therapeutics Market: Pipeline Assessment ..............................................................26
4.1 Overview........................................................................................................................................26
4.2 Strategic Pipeline Assessment ......................................................................................................26
4.2.1 Technology Trends Analytic Framework ..............................................................................26
4.3 Type 1 Diabetes Therapeutics – Promising Drugs under Clinical Development............................27
4.4 Molecule Profile for Promising Drugs under Clinical Development................................................28
4.4.1 rhGAD65 (Diamyd) ...............................................................................................................28
4.4.2 DiaPep277............................................................................................................................28
4.4.3 Otelixizumab.........................................................................................................................29
4.4.4 Oral-lyn.................................................................................................................................30
4.5 Type 1 Diabetes Therapeutics Market – Clinical Pipeline by Mechanism of Action.......................31
4.6 Type 1 Diabetes Pipeline – Pipeline by Clinical Phases of Development ......................................32
4.6.1 Type 1 Diabetes Therapeutics – Filed and Approved Drugs ................................................32
4.6.2 Type 1 Diabetes Therapeutics – Phase III Clinical Pipeline .................................................33
4.6.3 Type 1 Diabetes Therapeutics – Phase II Clinical Pipeline ..................................................33
4.6.4 Type 1 Diabetes Therapeutics – Phase I Clinical Pipeline ...................................................35
4.6.5 Type 1 Diabetes Therapeutics – Preclinical-Discovery Pipeline...........................................35
4.7 Key Takeaway ...............................................................................................................................36
5 Type 1 Diabetes Market: Implications for Future Market Competition..................................................37
6 Type Diabetes Therapeutics Market: Future Players in the Type 1 Diabetes Therapeutics Market .....39
6.1 Introduction....................................................................................................................................39
6.2 Novo Nordisk .................................................................................................................................39
6.2.1 Business Description ............................................................................................................39
6.2.2 Metabolic Disorders Portfolio................................................................................................40
6.2.3 Type 1 Diabetes Pipeline Portfolio........................................................................................41
6.3 GlaxoSmithKline ............................................................................................................................42
6.3.1 Business Description ............................................................................................................42
6.3.2 Metabolic Disorders Portfolio................................................................................................43
6.3.3 Type 1 Diabetes Pipeline Portfolio........................................................................................43
6.4 Eli Lilly ...........................................................................................................................................44
6.4.1 Business Description ............................................................................................................44
6.4.2 Metabolic Disorders Portfolio................................................................................................45
6.4.3 Type 1 Diabetes Pipeline Portfolio........................................................................................45
6.5 Sanofi-Aventis................................................................................................................................46
6.5.1 Business Description ............................................................................................................46
Type 1 Diabetes - Drug Pipeline Assessment and
Market Forecasts to 2017
GDHC106PRT /Published JUN 2010
Page 3
© GlobalData. This report is a licensed product and is not to be photocopied